Shared on 01 Nov 25
Fair value Increased 8.85%Analysts have raised GRAIL's fair value estimate from $56.50 to $61.50 per share, citing greater confidence in the company's platforms, ongoing clinical milestones, and evolving market opportunities as key drivers for the upward revision. Analyst Commentary Bullish Takeaways Bullish analysts highlight growing confidence in GRAIL's platforms.
Shared on 18 Oct 25
Analysts have raised their price target on GRAIL significantly, from $43 to $75. They cite growing confidence in the company's platforms, anticipated improvements in test performance, and the potential impact of future legislative changes as reasons for this adjustment.
Shared on 04 Oct 25
Fair value Increased 40%Analysts have raised their price target for GRAIL from $40.50 to $56.50. They cite strengthened confidence in the company's platforms, positive expectations for future study results, and anticipation of supportive legislative developments.